Eden Global Partners and The Age of Patient Capital
The breakthroughs that reshape industries are rarely the product of a single quarter. They are built over years, through uncertainty, by founders who need partners with the conviction to stay the course. That is the promise of patient capital, and the founding premise of Eden Global Partners.
Patient capital is not passive. In the right hands, it is the instrument by which the future gets built: deliberately, durably, and on the terms of those doing the building. Founders who can access it gain the freedom to pursue opportunities aligned with their mission rather than their last earnings call. Investors who can deploy it gain exposure to the highest-quality growth available — growth that has migrated, decisively and structurally, from public to private markets.
Eden stands at the intersection of patient capital and transformative companies. And it is the most consequential intersection in capital markets today.
The Great Migration
There has been a fundamental shift in how value gets built, and most investors have not caught up.
Since the 1990s, the number of listed US companies has been cut in half: from 8,000 to fewer than 4,000. The median time to IPO has doubled, from six years to twelve. Meanwhile, an estimated 1,700 private unicorns now exist globally, representing $5.8 trillion in value among US companies alone. Family offices, managing $6.1 trillion in assets and growing, on average, at 7.5% annually, are bypassing intermediaries and writing direct checks into the best private companies. Legislative tailwinds reinforced the shift: the 2012 JOBS Act expanded the shareholder threshold from 500 to 2,000, giving companies the freedom to build substantial capital bases without triggering public reporting obligations.
The result is a parallel universe of extraordinary scale, and extraordinary opacity for those without the right relationships to navigate it.
SpaceX is the defining example. Having raised over $9 billion in private markets since 2002, SpaceX went public in June 2026 at a ~$2 trillion valuation. Their path was far from linear. Early investors had to hold to their conviction, as the first three Falcon 1 launches failed before the fourth reached orbit in 2008. But by 2025 SpaceX delivered more than 80% of the payload mass sent to orbit, nearly 10 times their closest competitor.
The exploded rockets and years without profitability that characterized SpaceX’s early life would have been fatal for a public company. Their success was a function of a visionary founder, an ambitious mission, and the right capital partners for the journey. Staying the course in private markets bought SpaceX the time it needed to build an insurmountable moat in a category defined by long-term ambition.
The highest-quality businesses have taken notice, and are seeking high-quality partners. The question for investors is whether they are positioned to participate, or whether they will arrive, as most do, after the most significant value creation has already occurred.
Why Public Markets Fail the Best Companies
The IPO is not obsolete. For most companies, public markets remain the final destination: the capital available at scale in the public arena is unmatched. Founder-led businesses within the S&P 500 have delivered roughly 2x the outperformance of the broader index from 2015 to 2024. But timing is everything, and the cost of getting it wrong is severe.
Today’s public shareholder base has become increasingly hostile for young growth companies. Long-only investors with genuine conviction are scarce. What dominates instead is passive index capital, which flows primarily to already-indexed companies and largely bypasses newer entrants, alongside short-duration hedge funds whose strategies are measured in months. Many institutional investors are benchmark optimizers, focused on quarterly beats or misses rather than multi-year value creation. And most venture-backed companies would not even qualify for index inclusion, leaving them exposed to the worst of public markets with few of the benefits.
Rivian made this mistake in spectacular fashion. It debuted in November 2021 at roughly $70 billion on almost no revenue, a genuine technological vision subjected to delivery timelines the business was structurally unready to meet. The market showed no mercy. Peloton followed the same arc: a surge driven by the pandemic masked fundamental weaknesses in unit economics until the collapse made them impossible to ignore.
The companies that got it right share a common trait: they stayed private until they were ready. Reddit spent 19 years iterating before a successful IPO in 2024. Spotify achieved category dominance over a decade in private markets before entering by direct listing. CoreWeave built critical AI infrastructure away from public scrutiny, and debuted to extraordinary demand because the durable competitive position was already visible by the time public investors arrived.
The compounding effect of choosing the right moment, and the right partners, is not marginal. It is the difference between building an institution and being consumed by the market’s appetite for short-term signal.
The Liquidity Gap: A $3 Trillion Opportunity
The migration to private markets has produced a structural inefficiency of enormous scale, and Eden is built to unlock it.
Of the $7.3 trillion in venture-backed businesses globally, an estimated $3 trillion in value remains unrealized, with $1.7 trillion sitting in funds launched in 2019 or earlier. Direct secondaries change hands at a fraction of private market value: approximately 2% of total value annually, compared to public markets, which turn over roughly 68% of their $68.9 trillion US market capitalization each year.
This illiquidity has become a competitive threat. Between 2021 and 2023, Big Tech firms used Stripe’s illiquidity as a recruiting weapon, poaching engineers with the promise of publicly tradeable equity. Stripe responded with a structured tender offer, an early signal of the innovation now emerging in the liquidity solutions market. Anthropic and OpenAI have likewise allowed early employees and investors to sell a combined $14 billion over the last five years.
The lesson is clear. When Meta is willing to write nine-figure compensation packages to secure the world’s best AI engineers, illiquidity is not a neutral condition. It is a vulnerability.
Eden delivers scaled liquidity solutions for companies and existing investors, powered by a global network of capital partners aligned with management’s long-term vision. Our Liquidity Solution is the flagship instrument, purpose-built for a market where the demand for liquidity has far outpaced the supply of intelligent, aligned capital needed to provide it.
What This Means for Founders
The right investor at the right moment is a strategic unlock. The wrong one is a costly distraction. Companies that reach unicorn status raise 6.5 rounds of funding — the quality of judgement at each of these inflection points compounds.
One of the chief advantages of the private market is the ability to choose your own shareholders. Eden helps exceptional founders take full advantage of that freedom, advising on primary and secondary capital-raising with the network and selectivity to ensure that everyone on your cap table is genuinely aligned with where you are going.
Moderna was prepared to meet the moment during the pandemic in part because the investors on its cap table were aligned with its long-term vision, partners who stood ready to support the transformation of a research laboratory into an industrial-scale vaccine manufacturer. This partnership benefited not just a world-class company, but the world at large.
What This Means for Investors
A Morningstar index of the 20 largest late-stage venture-backed companies has delivered approximately 8.5x returns since 2015, compared to roughly 4x from US public markets. The highest growth is happening in private, and waiting for the IPO means arriving after the most significant value has already been created.
Airbnb spent twelve years building category dominance in private markets. The company hosted more than 1 billion stays and experiences before their IPO. By the time public investors arrived, the most consequential growth was already behind them — the stock has been largely flat since its 2020 debut. Tony Xu’s backers bought into the DoorDash flywheel — more consumers, more dashers, more merchants — and fueled their path to category leadership in the US. The model was proven, refined, and scaled, all in private markets.
But the return case for private markets demands more than patience. It demands judgment.
The risk of getting it wrong can be severe. WeWork raised $12.8 billion across 21 rounds over 11 years, sustained by investors seduced by high-velocity growth into overlooking a complete absence of governance discipline. Theranos sustained its fraudulent claims for over a decade behind the shield of private-market confidentiality. The flexibility and long time horizons that make private markets powerful can, in the wrong hands, become cover for deception or simple incompetence.
Power law economics also govern this asset class with unusual force. A small number of companies capture a disproportionate share of returns, and that concentration has accelerated dramatically with AI. The top 10 venture investments now account for 39% of total deal value, up from 6% three years ago.
Within the broader private equity ecosystem, growth has never been more important. 10 years ago investors required 5% annual EBITDA growth to generate a 20% IRR / 2.5x MOIC over a 5-year holding period. Today it’s more than doubled: 12% is the new 5%.
In this environment, access and judgment are precious resources. Eden curates the highest-quality opportunities for our investor network, deploying the relationships and selectivity that decades of transaction experience afford.
Meeting the Moment
Most capital comes with strings. Quarterly pressure. Misaligned time horizons. Investors who need the exit to be visible from day one. The founders building the most consequential companies of the next decade cannot afford those partners. They need capital that is prepared to commit, prepared to wait, and prepared to double down on transformative opportunities when others are losing their nerve.
Capital is not scarce. There is more of it in the world today than at any point in history, chasing a finite number of genuinely exceptional opportunities. What is scarce, extraordinarily scarce, is patient and intelligent capital deployed with conviction by people who have spent decades in the room with the best companies at the moments that matter most.
That is what Eden offers. Not just access to capital, but access to the right capital, on the right terms, from partners who have advised Palantir, Moderna, and Uber through the inflection points that defined them. The judgment that comes from that experience is not something that can be replicated. It is, like all truly scarce things, the result of time.
Time compounds incremental decisions into world-changing revolutions. It is a veil through which no one can see clearly — but those with the courage to peer ahead, and the right partners at their side, will shape what lies beyond it.
Patient capital does just that. And it is what Eden is built to deliver.
DISCLAIMER
These materials are being provided to you by Eden Global Partners LLC, Eden Global Capital Partners LLC or Eden Global Advisors LLC (collectively “Eden”) for informational purposes only. This transmission may contain confidential or proprietary information. No part of this material may be distributed or reproduced in any form, or referred to in any other publication, without express written permission.
Eden expressly disclaims any obligation or responsibility, express or implied, to update or supplement these materials or the information contained therein at any time. Although these materials have been prepared in good faith, neither Eden nor any of its employees, members, officers, directors, agents, representatives, and advisors make any representation or warranty concerning the accuracy or completeness of the materials or the information contained therein, or that it is sufficient or appropriate for the purpose of evaluating an investment in or conducting an assessment or valuation of a company. These materials do not constitute tax, legal, accounting, or investment advice; you should conduct your own evaluation of any potential investment and consult your own advisors.
These materials do not constitute an offer, solicitation or recommendation regarding any investment management product or service, or an offer to sell or the solicitation of an offer to buy any security; nor shall any such services be provided, or securities be offered or sold, in any jurisdiction in which such an offer, solicitation, provision or sale would be unlawful.
These materials contain forward-looking statements of future expectations that are based on current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Past performance is not indicative of future results. In addition to statements which are forward-looking by reason of context, the words “may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential, or continue” and similar expressions identify forward-looking statements. The views and opinions expressed are not predictions of future events and are subject to change.




